


ndd is the Expert in Lung Function Testing at the Point of Care

Diffusion capacity (DLCO) is the most powerful predictor of survival in COPD patients.¹



Why DLCO?

To predict severe exacerbations in COPD that would likely result in hospitalization or ER visit⁴



To monitor patients with drug induced pulmonary toxicity³




Differential diagnosis between asthma and emphysema²





To detect interstitial lung disease early, before spirometry and lung volumes become decreased²



Simple. Certain. Proven.

EasyOne Pro – Portable Pulmonary Function Testing at the point of care

EasyOne Pro® provides the **most efficient** and **accurate** way to test lung function in any setting. Engineered using our patented TrueFlow™ and TrueCheck™ technology, the EasyOne Pro® eliminates all sources of error, saves time and gives your patients the best pulmonary care in your practice or lung function lab.

DLCO testing adds only **5 minutes** to spirometry and doubles reimbursement

Instant interpretation of results with the ATS/ERS decision tree

Bringing the diagnosis **closer to the patient**with point of care testing



Proven worldwide:

NIH, COPDGene, GOLD, NASA, World Trade Center

All clinical statements come from these sources:

COPDGene, DLCO Influences Morbidity Beyond Spirometry and CT Evidence of Emphysema in COPDGene, May 2018¹ ATS/ERS, Interpretative strategies for lung function tests, April 2005² Consultant 360, Using and Interpreting Carbon Monoxide Diffusing Capacity (Dlco) Correctly, May 2016³ CHEST, Diffusing Capacity of Carbon Monoxide i Assessment of COPD, Oct 2019⁴